Brain Natriuretic Propeptide as a Marker of the Heart Damage in Metabolic Syndrome

Q: What are the key findings of this study?

Metabolic syndrome was associated with significantly higher NT-proBNP levels compared to controls (246.5 vs 24.33 pg/ml, p<0.0001).

Q: What is the clinical evidence from this study?

Study design: Case-Control. Population: Metabolic syndrome (n=148). Intervention: Metabolic syndrome vs. Controls without metabolic syndrome. Primary outcome: NT-proBNP level (p=<0.0001).

Q: What does this research mean for the field?

Patients with metabolic syndrome have significantly elevated circulating NT-proBNP levels compared to controls, with levels increasing alongside the severity of left ventricular diastolic dysfunction. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To examine the relationship between NT-proBNP levels, metabolic syndrome components, and left ventricular systolic and diastolic function in affected patients.

Р. А. Либис; Е. Н. Исаева; L. G. Vdovenko; И. Р. Басырова

doi:10.15829/1560-4071-2015-4-84-88

November 26, 2015Russian Journal of CardiologyOpen Access

Brain Natriuretic Propeptide as a Marker of the Heart Damage in Metabolic Syndrome

View Full Paper

Ask AI

Bookmark

Share

Key result

Metabolic syndrome linked to ~10-fold higher NT-proBNP levels versus controls.

P<0.0001
n=148

Why the study?

The relationship of NT-proBNP levels with metabolic syndrome components and left ventricular function in patients with metabolic syndrome was not well characterized.

Key Points

To examine the relationship between NT-proBNP levels, metabolic syndrome components, and left ventricular systolic and diastolic function in affected patients.
Evaluated 148 participants divided into 100 patients with metabolic syndrome defined by IDF (2005) criteria and 48 controls without metabolic syndrome.
Performed anthropometry, blood pressure measurement, glucose and lipid testing, serum NT-proBNP quantification, electrocardiography, and echocardiography across all participants.
Patients with metabolic syndrome had significantly higher circulating NT-proBNP concentrations than controls (246.5 ± 35.3 pg/ml vs 24.33 ± 4.7 pg/ml, p < 0.0001).
Left atrial diameter (P = 0.766, p = 0.001), interventricular septum thickness (P = 0.29, p = 0.04), OT (P = -0.217, p = 0.039), and triglycerides (P = -0.22, p = 0.04) independently correlated with NT-proBNP levels, which rose as diastolic dysfunction worsened.

Study Design

Type

Case-Control (n=148)

Structured PICO

P

Population

148 participants, comprising 100 patients with metabolic syndrome and 48 controls without metabolic syndrome.

C

Comparator

48 controls without metabolic syndrome

O

Outcome

NT-proBNP levels and their correlation with metabolic syndrome components and echocardiographic parameters of LV functionsurrogate

Main Result

Absolute Event Rate: 246.5% vs 24.33%

p-value: p=<0.0001

NT-proBNP levels are significantly elevated in patients with metabolic syndrome and correlate with diastolic dysfunction severity, suggesting its utility as a marker for early cardiac disorders.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Elevated NT-proBNP may signal subclinical cardiac dysfunction in metabolic syndrome; cross-sectional data leave its biomarker utility unproven.

Abstract

Aim. To study the relationship of NT-proBNP level with metabolic sindrome (MS) components and values of diastolic and systolic functions of the LV in patients with MS. Material and methods. Totally 148 patients studied. The main group consisted of 100 persons with MS, controls were 48 persons without MS. The participants underwent anthropometry, BP measurement, glucose level measurement, lipid spectrum, NT-proBNP levels and also ECG and EchoCG recording. MS and its components were evaluated according to IDF (2005). Results. MS patients had higher level of NT-proBNP than controls (246,5±35,3 pg/ml vs 24,33±4,7 pg/ml, p<0,0001). It was shown that the diameter of LA (P=0,766, p=0,001), IVST (P=0,29, p=0,04), ОТ (Р=-0,217, p=0,039) and level of TG (P=-0,22, p=0,04) are independent factors related to NT-proBNP. With an increase of diastolic dysfunction LV severity the level of NT-proBNP also increased. Conclusion. NT-proBNP reveals the patients with early cardial disorders among persons with MS.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Либис et al. (2015) conducted a case-control in Metabolic syndrome (n=148). Metabolic syndrome vs. Controls without metabolic syndrome was evaluated on NT-proBNP level (p=<0.0001). Metabolic syndrome was associated with significantly higher NT-proBNP levels compared to controls (246.5 vs 24.33 pg/ml, p<0.0001).

synapsesocial.com/papers/6aa81728bfbaf8fff0574b5d https://doi.org/10.15829/1560-4071-2015-4-84-88

View Full Paper

Ask AI

Bookmark

Share

Brain Natriuretic Propeptide as a Marker of the Heart Damage in Metabolic Syndrome

Key Points

Study Design

Structured PICO

Main Result

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Brain Natriuretic Propeptide as a Marker of the Heart Damage in Metabolic Syndrome

Key Points

Study Design

Structured PICO

Main Result

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading